Download Image
    
Share
  
Post
SNS812 for COVID-19
1 study with 90 patients
Significantly lower risk for recovery and viral clearance.
COVID-19 SNS812 studies. Sep 2026. c19early.org
0 0.5 1 1.5+ All studies 52% Viral clearance 14% RCTs 52% Early 52% FavorsSNS812 Favorscontrol
Recent:
Chen.
Mar 11
2025
 Chen et al., Journal of Biomedical Science, doi:10.1186/s12929-026-01284-5 (results released 3/11/2025) Safety and antiviral activity of inhaled siRNA SNS812 for treatment of mild-to-moderate COVID-19: a phase 2 randomized trial
52% improved recovery (p=0.002), 45% greater improvement (p=0.01), 14% improved viral load (p=0.04), and 19% faster viral clearance (p=0.007). RCT 135 patients with mild to moderate COVID-19 showing significant efficacy of inhaled SNS812 (siRNA targeting SARS-CoV-2 RdRP) for reducing viral load and accelerating symptom resolution. The trial randomized patients to 200mg, 100mg, o..